The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure

Alan Maisel, Yang Xue, Stephen J. Greene, Peter S. Pang, James L. Januzzi, Ileana L. Pina, Christopher Defilippi, Javed Butler

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25% of these patients are rehospitalized within 30 days, and 30% are dead within 1 year. To date, all trials in patients with acute HF (AHF) have failed to improve post-discharge outcomes. There remains a need for an effective objective risk stratification strategy that is capable of reliably identifying patients at heightened risk for readmission and informing discharge decision making. Natriuretic peptide (NP) levels during and after AHF hospitalization can provide valuable information regarding congestion status and chronic remodeling stress. The lack of sensitivity and inter-rater reliability of physical examination, and failure to achieve dry weight in many patients before discharge, renders the use of NP to guide therapy to prevent readmission an attractive option. NP levels can be used across the spectrum of AHF care settings, ranging from the emergency department and inpatient stay to post-discharge follow-up and chronic management. This review summarizes available data and provides an expert opinion on the potential role of NPs to reduce HF readmissions.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalJournal of Cardiac Failure
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Natriuretic Peptides
Heart Failure
Hospitalization
Patient Discharge
Expert Testimony
Physical Examination
Hospital Emergency Service
Inpatients
Decision Making
Weights and Measures
Therapeutics

Keywords

  • Heart failure
  • hospitalization
  • natriuretic peptides
  • readmission

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. / Maisel, Alan; Xue, Yang; Greene, Stephen J.; Pang, Peter S.; Januzzi, James L.; Pina, Ileana L.; Defilippi, Christopher; Butler, Javed.

In: Journal of Cardiac Failure, Vol. 21, No. 3, 01.03.2015, p. 233-239.

Research output: Contribution to journalArticle

Maisel, Alan ; Xue, Yang ; Greene, Stephen J. ; Pang, Peter S. ; Januzzi, James L. ; Pina, Ileana L. ; Defilippi, Christopher ; Butler, Javed. / The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. In: Journal of Cardiac Failure. 2015 ; Vol. 21, No. 3. pp. 233-239.
@article{36dede4bb87441ff80b1b90c6c1d4786,
title = "The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure",
abstract = "There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25{\%} of these patients are rehospitalized within 30 days, and 30{\%} are dead within 1 year. To date, all trials in patients with acute HF (AHF) have failed to improve post-discharge outcomes. There remains a need for an effective objective risk stratification strategy that is capable of reliably identifying patients at heightened risk for readmission and informing discharge decision making. Natriuretic peptide (NP) levels during and after AHF hospitalization can provide valuable information regarding congestion status and chronic remodeling stress. The lack of sensitivity and inter-rater reliability of physical examination, and failure to achieve dry weight in many patients before discharge, renders the use of NP to guide therapy to prevent readmission an attractive option. NP levels can be used across the spectrum of AHF care settings, ranging from the emergency department and inpatient stay to post-discharge follow-up and chronic management. This review summarizes available data and provides an expert opinion on the potential role of NPs to reduce HF readmissions.",
keywords = "Heart failure, hospitalization, natriuretic peptides, readmission",
author = "Alan Maisel and Yang Xue and Greene, {Stephen J.} and Pang, {Peter S.} and Januzzi, {James L.} and Pina, {Ileana L.} and Christopher Defilippi and Javed Butler",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.cardfail.2014.11.009",
language = "English (US)",
volume = "21",
pages = "233--239",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure

AU - Maisel, Alan

AU - Xue, Yang

AU - Greene, Stephen J.

AU - Pang, Peter S.

AU - Januzzi, James L.

AU - Pina, Ileana L.

AU - Defilippi, Christopher

AU - Butler, Javed

PY - 2015/3/1

Y1 - 2015/3/1

N2 - There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25% of these patients are rehospitalized within 30 days, and 30% are dead within 1 year. To date, all trials in patients with acute HF (AHF) have failed to improve post-discharge outcomes. There remains a need for an effective objective risk stratification strategy that is capable of reliably identifying patients at heightened risk for readmission and informing discharge decision making. Natriuretic peptide (NP) levels during and after AHF hospitalization can provide valuable information regarding congestion status and chronic remodeling stress. The lack of sensitivity and inter-rater reliability of physical examination, and failure to achieve dry weight in many patients before discharge, renders the use of NP to guide therapy to prevent readmission an attractive option. NP levels can be used across the spectrum of AHF care settings, ranging from the emergency department and inpatient stay to post-discharge follow-up and chronic management. This review summarizes available data and provides an expert opinion on the potential role of NPs to reduce HF readmissions.

AB - There are >1 million hospitalizations for heart failure (HF) in the United States annually. After discharge, 25% of these patients are rehospitalized within 30 days, and 30% are dead within 1 year. To date, all trials in patients with acute HF (AHF) have failed to improve post-discharge outcomes. There remains a need for an effective objective risk stratification strategy that is capable of reliably identifying patients at heightened risk for readmission and informing discharge decision making. Natriuretic peptide (NP) levels during and after AHF hospitalization can provide valuable information regarding congestion status and chronic remodeling stress. The lack of sensitivity and inter-rater reliability of physical examination, and failure to achieve dry weight in many patients before discharge, renders the use of NP to guide therapy to prevent readmission an attractive option. NP levels can be used across the spectrum of AHF care settings, ranging from the emergency department and inpatient stay to post-discharge follow-up and chronic management. This review summarizes available data and provides an expert opinion on the potential role of NPs to reduce HF readmissions.

KW - Heart failure

KW - hospitalization

KW - natriuretic peptides

KW - readmission

UR - http://www.scopus.com/inward/record.url?scp=84923546326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923546326&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2014.11.009

DO - 10.1016/j.cardfail.2014.11.009

M3 - Article

VL - 21

SP - 233

EP - 239

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 3

ER -